Promising drug combo aims to shrink breast tumors before surgery

This study tests whether adding the targeted drug pyrotinib to standard chemotherapy can better shrink tumors before surgery in people with a common type of early breast cancer (HR-positive, HER2-low). About 160 adults with high-risk, early-stage breast cancer will be randomly assigned to receive either the drug combo or chemo alone. The main goal is to see if the combo leads to less cancer remaining in the breast tissue after treatment.